Home » Stocks » Mesoblast

Mesoblast Limited (MESO)

Stock Price: $15.50 USD -0.23 (-1.46%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
After-hours: $15.72 +0.22 (1.42%) Aug 6, 6:04 PM

Stock Price Chart

Key Info

Market Cap 1.80B
Revenue (ttm) 33.42M
Net Income (ttm) -89.80M
Shares Out 116.79M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE 114.94
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $15.50
Previous Close $15.73
Change ($) -0.23
Change (%) -1.46%
Day's Open 15.64
Day's Range 15.29 - 15.72
Day's Volume 297,706
52-Week Range 3.12 - 20.57

More Stats

Market Cap 1.80B
Enterprise Value 1.83B
Earnings Date (est) Sep 1, 2020
Ex-Dividend Date n/a
Shares Outstanding 116.79M
Float 84.35M
EPS (basic) -0.908
EPS (diluted) -0.64
FCF / Share -0.60
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.06M
Short Ratio 2.36
Short % of Float n/a
Beta 2.69
PE Ratio n/a
Forward PE 114.94
P/FCF Ratio n/a
PS Ratio 53.85
PB Ratio 3.27
Revenue 33.42M
Operating Income -81.16M
Net Income -89.80M
Free Cash Flow -58.07M
Net Cash -30.86M
Net Cash / Share -0.27
Gross Margin 4.08%
Operating Margin -242.84%
Profit Margin -537.00%
FCF Margin -173.74%
ROA -5.63%
ROE -13.36%
ROIC -108.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$17.04*
(9.94% upside)
Low
7.52
Current: $15.50
High
23.00
Target: 17.04
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue16.7217.342.4142.5519.7623.3929.30
Revenue Growth-3.57%618.95%-94.33%115.31%-15.52%-20.17%-
Gross Profit16.7217.342.4142.5519.7623.3929.30
Operating Income-81.16-74.69-90.09-119-80.91-71.20-66.15
Net Income-89.80-35.29-76.82-4.13-96.24-75.53-62.12
Shares Outstanding483428381366366--
Earnings Per Share-0.91-0.38-0.96-0.06-1.50-1.18-1.05
Operating Cash Flow-57.79-75.01-95.47-88.00-101-74.91-55.75
Capital Expenditures-0.28-0.20-0.31-0.72-2.20-1.71-1.27
Free Cash Flow-58.07-75.21-95.78-88.72-103-76.62-57.01
Cash & Equivalents50.4337.7645.7680.941111850.00
Total Debt81.2959.40-----
Net Cash / Debt-30.86-21.6345.7680.941111850.00
Assets652692656684782847-
Liabilities171146139156314309-
Book Value481546517528468539-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mesoblast Limited
Employees 83
CEO Silviu Itescu

Stock Information

Ticker Symbol MESO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MESO

Description

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.